Working… Menu

The Extended Gestational Age Medical Abortion Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00997347
Recruitment Status : Completed
First Posted : October 19, 2009
Last Update Posted : July 2, 2012
Information provided by (Responsible Party):
Gynuity Health Projects

Brief Summary:
This open-label, comparative study will compare the efficacy, safety, and acceptability of 200 mg mifepristone followed in 24-48 hours by 800mcg buccal misoprostol or 400mcg sublingual misoprostol for termination of pregnancy in existing outpatient early medical abortion services among women 57-63 days' versus 64-70 days' gestation.

Condition or disease Intervention/treatment Phase
Medical Abortion Drug: Mifepristone and misoprostol Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1400 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation
Study Start Date : July 2009
Actual Primary Completion Date : February 2012
Actual Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 64-70 days' gestational age
Women whose pregnancies are estimated to have a gestational age of 64-70 days
Drug: Mifepristone and misoprostol

200 mg oral mifepristone

800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone

No Intervention: 57-63 days' gestational age
Women whose pregnancies are estimated to have a gestational age of 57-63 days. (Women in this arm receive the standard of care for medical termination of pregnancy in the stated gestational age range.)

Primary Outcome Measures :
  1. Efficacy: Proportion of women who successfully complete abortion without surgical intervention to resolve viable pregnancy or incomplete abortion [ Time Frame: 7-36 days ]

Secondary Outcome Measures :
  1. Proportion of individual side effects experienced by participants [ Time Frame: 7-14 days ]
  2. Proportion of women who determined method acceptable (i.e., overall acceptability of method, time to abortion completion, bleeding, side effects, and pain) [ Time Frame: 7-14 days ]
  3. Bleeding patterns, i.e. proportion of women who experienced heavy, moderate, or light bleeding according by day since abortion began [ Time Frame: 7-14 days ]
  4. Average number of missed days of work or school due to the abortion procedure [ Time Frame: 7-14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • intrauterine pregnancy of greater than 56 days and less than 71 days
  • eligible for medical abortion according to study doctor assessment
  • willing and able to sign consent forms
  • speak English or Spanish (in US sites); speak the local language(s) (in international sites)
  • agree to comply with the study procedures and visit schedule

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00997347

Layout table for location information
United States, Florida
Presidential Women's Center
West Palm Beach, Florida, United States, 33407
United States, Illinois
Family Planning Associates Medical Group
Chicago, Illinois, United States, 60630
United States, Massachusetts
Planned Parenthood League of Massachusetts
Boston, Massachusetts, United States, 02215
United States, Minnesota
Planned Parenthood, Minnesota, North Dakota, South Dakota
St. Paul, Minnesota, United States, 55116
United States, New York
Planned Parenthood of New York City
New York, New York, United States, 10012
United States, Texas
Planned Parenthood, Central Texas
Waco, Texas, United States, 76710
Zhordania Institute of Human Reproduction
Tblisi, Georgia
Government Medical College (GMC)
Nagpur, India
Naval Nursing Home
Solapur, India
La Rabta Maternity Hospital
Tunis, Tunisia
Central District Maternity House
Odessa, Ukraine
Maternity Hospital No.2
Simferopol, Ukraine
Sponsors and Collaborators
Gynuity Health Projects
Layout table for investigator information
Principal Investigator: Yael Swica, MD, MPH Gynuity Health Projects
Principal Investigator: Hillary Bracken, PhD Gynuity Health Projects
Principal Investigator: Beverly Winikoff, MD, MPH Gynuity Health Projects
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Gynuity Health Projects Identifier: NCT00997347    
Other Study ID Numbers: 1.2.2
First Posted: October 19, 2009    Key Record Dates
Last Update Posted: July 2, 2012
Last Verified: June 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Anti-Ulcer Agents
Gastrointestinal Agents
Abortifacient Agents, Steroidal
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Contraceptives, Postcoital, Synthetic
Contraceptives, Postcoital
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Luteolytic Agents
Menstruation-Inducing Agents